The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 05 Jun 2017
At a glance
- Drugs Apalutamide (Primary) ; LHRH receptor agonists
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Aragon Pharmaceuticals; Johnson & Johnson
- 07 Jun 2017 Biomarkers information updated
- 30 Sep 2016 Status changed from recruiting to active, no longer recruiting.
- 23 Mar 2015 Planned End Date changed from 1 Feb 2018 to 1 Jan 2020 as reported by ClinicalTrials.gov record.